Disease Markers

Molecular Biomarkers and Imaging Markers in the Prediction, Diagnosis, and Prognosis of Heart Diseases


Publishing date
01 Mar 2021
Status
Published
Submission deadline
16 Oct 2020

1Medical University of Lodz, Poland

2Umeå University, Sweden

3Department of Hypertension, Medical University of Lodz, Lodz 90-549, Poland

4Department of Medical Biotechnology, Medical University of Lodz, Poland


Molecular Biomarkers and Imaging Markers in the Prediction, Diagnosis, and Prognosis of Heart Diseases

Description

Heart disease describes a range of conditions that affect the heart muscle and is the leading cause of death in many countries. One in every four deaths in the U.S. occurs as a result of heart disease. Diseases under the heart disease umbrella include blood vessel diseases, such as coronary artery disease; heart rhythm problems (arrhythmias); congenital heart defects and cardiomyopathies, valve diseases, myocarditis and many others. Heart disease may also be a consequence of other diseases such as hypertension, diabetes, and rheumatic diseases.

Biomarkers are tools used to more accurately identify high-risk individuals, to speed the diagnosis, and to help in treatment and prognosis determination. Biomarkers can be classified based on different parameters, including their characteristics, such as imaging biomarkers (echocardiography, computed tomography, magnetic resonance imaging) or molecular biomarkers.

The goal of this Special Issue is to summarize new advances in both molecular and imaging biomarkers of heart diseases, especially in risk prediction, screening, diagnosis, and prognosis. Original research and review articles are both welcome in order to best understand the importance of different biomarkers in heart diseases.

Potential topics include but are not limited to the following:

  • Advances in molecular biomarkers and heart diseases
  • Advances in imaging biomarkers and heart disease
  • The synergy of molecular and imaging biomarkers in predicting and detecting heart diseases
  • The synergy of molecular and imaging biomarkers in the assessment of prognosis in heart disease
  • Biomarkers for the evaluation of heart toxicity from chemo- and radiotherapy

Articles

  • Special Issue
  • - Volume 2020
  • - Article ID 8880004
  • - Research Article

Identification of Featured Metabolism-Related Genes in Patients with Acute Myocardial Infarction

Hang Xie | Enfa Zha | Yushun Zhang
  • Special Issue
  • - Volume 2020
  • - Article ID 8821961
  • - Research Article

Reversed Septal Curvature Is Associated with Elevated Troponin Level in Hypertrophic Cardiomyopathy

Renata Rajtar-Salwa | Tomasz Tokarek | Paweł Petkow Dimitrow
  • Special Issue
  • - Volume 2020
  • - Article ID 8864322
  • - Research Article

MicroRNA-216a Promotes Endothelial Inflammation by Smad7/IκBα Pathway in Atherosclerosis

Shujun Yang | Yu Chen | ... | Weili Zhang
  • Special Issue
  • - Volume 2020
  • - Article ID 8885189
  • - Research Article

Accurate Noninvasive Assessment of Myocardial Iron Load in Advanced Heart Failure Patients

Przemysław Leszek | Barbara Sochanowicz | ... | Marcin Kruszewski
  • Special Issue
  • - Volume 2020
  • - Article ID 8821029
  • - Review Article

Th17/Treg Imbalance and Atherosclerosis

Xin He | Bo Liang | Ning Gu
  • Special Issue
  • - Volume 2020
  • - Article ID 8847211
  • - Research Article

Catestatin as a New Prognostic Marker in Stable Patients with Heart Failure with Reduced Ejection Fraction in Two-Year Follow-Up

Łukasz Wołowiec | Daniel Rogowicz | ... | Grzegorz Grześk
  • Special Issue
  • - Volume 2020
  • - Article ID 8847635
  • - Research Article

A Novel Gene Signature to Predict Survival Time and Incident Ventricular Arrhythmias in Patients with Dilated Cardiomyopathy

Chenliang Ge | Yan He
Disease Markers
 Journal metrics
See full report
Acceptance rate6%
Submission to final decision131 days
Acceptance to publication42 days
CiteScore3.700
Journal Citation Indicator-
Impact Factor-

We have begun to integrate the 200+ Hindawi journals into Wiley’s journal portfolio. You can find out more about how this benefits our journal communities on our FAQ.